

Douglas S Krakower

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109332/publications.pdf>

Version: 2024-02-01

86
papers

3,365
citations

126708

33
h-index

155451

55
g-index

87
all docs

87
docs citations

87
times ranked

2707
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV Providersâ€™ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study. <i>AIDS and Behavior</i> , 2014, 18, 1712-1721.	1.4	259
2	Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. <i>PLoS ONE</i> , 2012, 7, e33119.	1.1	222
3	Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. <i>AIDS and Behavior</i> , 2015, 19, 802-810.	1.4	155
4	Integrating HIV Preexposure Prophylaxis (PrEP) Into Routine Preventive Health Care to Avoid Exacerbating Disparities. <i>American Journal of Public Health</i> , 2017, 107, 1883-1889.	1.5	135
5	The role of healthcare providers in the roll out of preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 41-48.	1.5	116
6	Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 119-127.	0.9	108
7	Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling study. <i>Lancet HIV</i> , 2019, 6, e688-e695.	2.1	105
8	Putting PrEP into Practice: Lessons Learned from Early-Adopting U.S. Providersâ€™ Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated Care. <i>PLoS ONE</i> , 2016, 11, e0157324.	1.1	102
9	Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). <i>AIDS and Behavior</i> , 2016, 20, 1400-1407.	1.4	91
10	Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. <i>PLoS ONE</i> , 2015, 10, e0132398.	1.1	90
11	Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. <i>Journal of General Internal Medicine</i> , 2017, 32, 192-198.	1.3	88
12	Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study. <i>Lancet HIV</i> , 2019, 6, e696-e704.	2.1	87
13	Evolution of Massachusetts Physician Attitudes, Knowledge, and Experience Regarding the Use of Antiretrovirals for HIV Prevention. <i>AIDS Patient Care and STDs</i> , 2012, 26, 395-405.	1.1	84
14	Engaging healthcare providers to implement HIV pre-exposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 593-599.	1.5	76
15	Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. <i>Journal of the International AIDS Society</i> , 2019, 22, e25250.	1.2	74
16	Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges. <i>Drugs</i> , 2015, 75, 243-251.	4.9	67
17	Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 684-693.	0.6	65
18	A Closer Look at Racism and Heterosexism in Medical Studentsâ€™ Clinical Decision-Making Related to HIV Pre-Exposure Prophylaxis (PrEP): Implications for PrEP Education. <i>AIDS and Behavior</i> , 2018, 22, 1122-1138.	1.4	65

#	ARTICLE	IF	CITATIONS
19	Artificial Intelligence and Machine Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic. <i>Current HIV/AIDS Reports</i> , 2020, 17, 171-179.	1.1	62
20	Antiretrovirals for Primary HIV Prevention: the Current Status of Pre- and Post-exposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2015, 12, 127-138.	1.1	61
21	“Support Your Client at the Space That They're in” HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 196-204.	1.1	58
22	Culturally Competent Sexual Healthcare as a Prerequisite for Obtaining Preexposure Prophylaxis: Findings from a Qualitative Study. <i>LGBT Health</i> , 2017, 4, 310-314.	1.8	57
23	Risk Compensation and Clinical Decision Making – The Case of HIV Preexposure Prophylaxis. <i>New England Journal of Medicine</i> , 2019, 380, 510-512.	13.9	55
24	Sexual Stereotypes Ascribed to Black Men Who Have Sex with Men: An Intersectional Analysis. <i>Archives of Sexual Behavior</i> , 2018, 47, 143-156.	1.2	54
25	Drug Resistance During HIV Pre-Exposure Prophylaxis. <i>Drugs</i> , 2019, 79, 609-619.	4.9	54
26	Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. <i>Journal of the International AIDS Society</i> , 2015, 18, 19980.	1.2	53
27	Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. <i>Aids</i> , 2017, 31, 2179-2191.	1.0	51
28	Prevention paradox: Medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. <i>Journal of the International AIDS Society</i> , 2018, 21, e25147.	1.2	43
29	Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. <i>AIDS and Behavior</i> , 2016, 20, 1499-1513.	1.4	41
30	Pre-exposure prophylaxis for HIV prevention in women: current perspectives. <i>International Journal of Women's Health</i> , 2017, Volume 9, 391-401.	1.1	41
31	Differing Experiences with Pre-Exposure Prophylaxis in Boston Among Lesbian, Gay, Bisexual, and Transgender Specialists and Generalists in Primary Care: Implications for Scale-Up. <i>AIDS Patient Care and STDs</i> , 2017, 31, 297-304.	1.1	39
32	The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention. <i>Clinical Infectious Diseases</i> , 2015, 60, S200-S204.	2.9	37
33	Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation. <i>Current Infectious Disease Reports</i> , 2019, 21, 28.	1.3	36
34	A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies. <i>Current HIV/AIDS Reports</i> , 2020, 17, 643-653.	1.1	35
35	HIV Preexposure Prophylaxis as a Gateway to Primary Care. <i>American Journal of Public Health</i> , 2018, 108, 1418-1420.	1.5	34
36	Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians. <i>Clinical Infectious Diseases</i> , 2016, 62, 99-105.	2.9	33

#	ARTICLE	IF	CITATIONS
37	HIV preexposure prophylaxis for adolescents and young adults. <i>Current Opinion in Pediatrics</i> , 2017, 29, 399-406.	1.0	33
38	What Primary Care Providers Need to Know About Preexposure Prophylaxis for HIV Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 490.	2.0	32
39	Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile. <i>BMC Infectious Diseases</i> , 2017, 17, 707.	1.3	32
40	“Don't Need PrEP Right Now”: A Qualitative Exploration of the Barriers to PrEP Care Engagement Through the Application of the Health Belief Model. <i>AIDS Education and Prevention</i> , 2018, 30, 369-381.	0.6	28
41	Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. <i>BMC Infectious Diseases</i> , 2017, 17, 702.	1.3	26
42	Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?. <i>Annals of Internal Medicine</i> , 2020, 172, 281.	2.0	24
43	Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications. <i>Current HIV/AIDS Reports</i> , 2011, 8, 241-248.	1.1	23
44	Public Health Detailing for Human Immunodeficiency Virus Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2019, 68, 860-864.	2.9	22
45	Editorial Commentary: Scaling Up Antiretroviral Preexposure Prophylaxis: Moving From Trials to Implementation. <i>Clinical Infectious Diseases</i> , 2015, 61, 1598-1600.	2.9	21
46	Using HIV Risk Prediction Tools to Identify Candidates for Pre-Exposure Prophylaxis: Perspectives from Patients and Primary Care Providers. <i>AIDS Patient Care and STDs</i> , 2019, 33, 372-378.	1.1	21
47	Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. <i>Journal of the International AIDS Society</i> , 2016, 19, 21165.	1.2	20
48	US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats. <i>Clinical Infectious Diseases</i> , 2019, 69, 884-889.	2.9	20
49	PrEP Product Acceptability and Dual Process Decision-Making Among Men Who Have Sex with Men. <i>Current HIV/AIDS Reports</i> , 2020, 17, 161-170.	1.1	17
50	iAIDS: HIV-Related Internet Resources for the Practicing Clinician. <i>Clinical Infectious Diseases</i> , 2010, 51, 813-822.	2.9	15
51	Using electronic health records to identify candidates for human immunodeficiency virus pre-exposure prophylaxis: An application of super learning to risk prediction when the outcome is rare. <i>Statistics in Medicine</i> , 2020, 39, 3059-3073.	0.8	15
52	Patient-Led Decision-Making for HIV Preexposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2021, 18, 48-56.	1.1	15
53	Optimizing Provider Preexposure Prophylaxis (PrEP) Training: A Cross-Sectional Analysis of Recommendations from Providers Across the PrEP Implementation Cascade. <i>AIDS and Behavior</i> , 2022, 26, 218-231.	1.4	15
54	Sexual Behavior Patterns and PrEP Dosing Preferences in a Large Sample of North American Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 94-101.	0.9	14

#	ARTICLE	IF	CITATIONS
55	The Promise of Antiretrovirals for HIV Prevention. <i>Current Infectious Disease Reports</i> , 2012, 14, 185-193.	1.3	13
56	A Pre-Exposure Prophylaxis Adherence Intervention (LifeSteps) for Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019, 8, e10661.	0.5	13
57	An Experimental Study of the Effects of Patient Race, Sexual Orientation, and Injection Drug Use on Providers'™ PrEP-Related Clinical Judgments. <i>AIDS and Behavior</i> , 2022, 26, 1393-1421.	1.4	13
58	Differences in PrEP Knowledge and Use in U.S. MSM Users of a Popular Sexual Networking Site Surveyed in August 2013 and January 2014. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A91-A92.	0.5	12
59	Structural Stigma Affects Access to Pre- and Post-exposure Prophylaxis and HIV Risk among Men Who Have Sex with Men (MSM) in the United States. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A22-A23.	0.5	10
60	Peering Through the Glass Ceiling: A Mixed Methods Study of Faculty Perceptions of Gender Barriers to Academic Advancement in Infectious Diseases. <i>Journal of Infectious Diseases</i> , 2020, 222, S528-S534.	1.9	10
61	Drawing from the Theory of Planned Behaviour to examine pre-exposure prophylaxis uptake intentions among heterosexuals in high HIV prevalence neighbourhoods in Philadelphia, Pennsylvania, USA: an observational study. <i>Sexual Health</i> , 2019, 16, 218-224.	0.4	9
62	Primary Care Providers'™ Perspectives on Using Automated HIV Risk Prediction Models to Identify Potential Candidates for Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2021, 25, 3651-3657.	1.4	8
63	Antiretrovirals for HIV Treatment and Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 151.	3.8	7
64	<i>Editorial Commentary:</i> Uncoupling Epidemiological Synergy: New Opportunities for HIV Prevention for Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 61, 288-290.	2.9	5
65	Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab372.	0.4	5
66	Academic Detailing to Increase Prescribing of HIV Pre-exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2021, 61, S87-S97.	1.6	4
67	Making PrEP easy. <i>Lancet HIV</i> , 2022, 9, e226-e228.	2.1	4
68	Let's Be a Person to Person and Have a Genuine Conversation: Comparing Perspectives on PrEP and Sexual Health Communication Between Black Sexual Minority Men and Healthcare Providers. <i>Archives of Sexual Behavior</i> , 2022, 51, 2583-2601.	1.2	4
69	Automated Identification of Potential Candidates for Human Immunodeficiency Virus Pre-exposure Prophylaxis Using Electronic Health Record Data. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	3
70	Antiretroviral Preexposure Prophylaxis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 867.	3.8	3
71	Working Toward Broad and Equitable Access to HIV Preexposure Prophylaxis. <i>American Journal of Public Health</i> , 2019, 109, 1160-1161.	1.5	2
72	Routine screening for hepatitis C in MSM on HIV PrEP. <i>Nature Reviews Urology</i> , 2019, 16, 272-274.	1.9	2

#	ARTICLE	IF	CITATIONS
73	Heterosexual Men Anticipate Risk Compensatory Behaviors With Future Preexposure Prophylaxis Initiation: Findings From an Exploratory Cross-Sectional Study. <i>Sexually Transmitted Diseases</i> , 2019, 46, e97-e100.	0.8	2
74	Machine Learning for Human Immunodeficiency Virus Prevention in Rural Africa: The SEARCH for Sustainability. <i>Clinical Infectious Diseases</i> , 2020, 71, 2334-2335.	2.9	2
75	Tenofovir Alafenamide for HIV Preexposure Prophylaxis. <i>Annals of Internal Medicine</i> , 2020, 173, 78.	2.0	2
76	Influence of Increasing Age and Body Mass Index of Gender in COVID-19 Patients. <i>Journal of Women's Health</i> , 2022, 31, 779-786.	1.5	2
77	Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?. <i>Journal of Infectious Diseases</i> , 2016, 214, 983-985.	1.9	1
78	HIV protection with PrEP " implications for controlling other STIs. <i>Nature Reviews Urology</i> , 2016, 13, 72-74.	1.9	1
79	Top Questions in ID: Pre-exposure Prophylaxis for HIV. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx185.	0.4	1
80	Human Immunodeficiency Virus Preexposure Prophylaxis: Meeting the Needs of Transgender Populations. <i>Clinical Infectious Diseases</i> , 2020, 73, e2124-e2126.	2.9	1
81	O09.5...Prep awareness, eligibility, and acceptability among heterosexuals recruited from community-based hiv testing sites. , 2017, , .		0
82	1317. Online Simulation-Based Education to Improve Primary Care Providers' Knowledge About Best Practices in HIV Preexposure Prophylaxis Care. <i>Open Forum Infectious Diseases</i> , 2018, 5, S402-S403.	0.4	0
83	Marcus et al. Respond. <i>American Journal of Public Health</i> , 2018, 108, e27-e28.	1.5	0
84	What do we say about condoms in 2019?. <i>Lancet HIV,the</i> , 2020, 7, e82-e83.	2.1	0
85	136. In Their Own words: a Qualitative Analysis of Factors Contributing to Gender Bias in Academic Advancement in Infectious Disease. <i>Open Forum Infectious Diseases</i> , 2020, 7, S198-S198.	0.4	0
86	587. Equity in academic advancement: findings from an IDSA-sponsored survey of infectious disease physicians. <i>Open Forum Infectious Diseases</i> , 2020, 7, S357-S357.	0.4	0